CODX logo

CO-DIAGNOSTICS INC

CODXNASDAQ
πŸ† #5059 by market capUS Equity
β€”β€”
Quote unavailable
πŸ””
Track CODX
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$4M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-28.1%
Declining
πŸ“ŠGross Margin
43.5%
Healthy
πŸ’΅FCF Margin
1969.6%
Strong
βš–οΈP/S Ratio
5.9x
Fair
Otter Score
β€”
Insufficient data
No chart data available for CODX.

Trading Snapshot

Day Range
β€”
52-Week Range
$0.53 – $46.50
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
6.8M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
$622,489
Last Q Revenue
$166,131
P/E Ratio
β€”
P/S Ratio
5.9x
EPS (TTM)
$-23.84
Dividend Yield
β€”
Dilution (1yr)
+20.7%
CODX logo

CO-DIAGNOSTICS INC

CODX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$622Kβ–Ό βˆ’84.1% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
64.3%β–Ό βˆ’13.7% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$31Mβ–Ό βˆ’22.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$30Mβ–Ό βˆ’0.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
1.3Mβ–² +20.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$11Mβ–² +$10M YoY
StockOtter Β· stockotter.space

About CO-DIAGNOSTICS INC

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.